TWIST BIOSCIENCE ANTIBODY DISCOVERY AGREEMENTAntibody Discovery Agreement • November 8th, 2022 • Adicet Bio, Inc. • Pharmaceutical preparations • Delaware
This Antibody Discovery Agreement (“Agreement”) is entered into as of the Effective Date set forth below by and between Twist Bioscience Corporation, a Delaware corporation (“Twist”) and the customer identified below (“Company”) for the purpose of Twist providing performing certain antibody discovery activities, all as described under and subject to the terms and conditions of this Agreement below. Company and Twist may be referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO ANTIBODY DISCOVERY AGREEMENT AND PROJECT ORDER NO. [***]Antibody Discovery Agreement • March 15th, 2023 • Adicet Bio, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT (this “Amendment”), effective as of November 8, 2022 (the “Amendment Date”), is entered into by and between Twist Bioscience Corporation, with an address of 681 Gateway Boulevard, South San Francisco, CA 94080 (“Twist”) and Adicet Therapeutics, Inc., a Delaware corporation, with a principal place of business at 1000 Bridge Parkway Redwood City, 94065 (“Customer”). Each of Twist and Customer may be referred to herein as a “Party” and together as the “Parties”.
